康乃德生物医药:预设定中期分析后,Seabreeze二期研究将按计划继续推进患者入组

美股速递
Apr 23

康乃德生物医药控股有限公司宣布,其Seabreeze二期临床试验在完成预设的中期分析后,决定按原定方案持续推进患者招募工作。此项分析旨在评估研究的有效性与安全性参数,结果表明当前试验进展符合预期轨迹,支持继续开展后续研究阶段。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10